Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Summary
This study of 402 cases of stable angina subjects who were diagnosed as Coronary Heart Disease (CHD) is a randomized, blank controlled, multi-center clinical study. Subjects who are taking standard treatment with stable symptoms will receive a 24-hour ambulatory electrocardiogram (ECG) (Holter) examination. They will be randomly divided into two groups. The nicorandil group will receive nicorandil 5 milligram (mg) (3 times a day = tid) on top of the standard treatment for 12 weeks, while the control group will stay on standard treatment. Nitrates and beta blockers need to be maintained on a stable dose. Other drugs that do not affect the primary endpoint may be adjusted per investigators decision.
Timeline
- Start
- 2011-09
- Primary completion
- 2014-05
- Completion
- 2014-05
Outcome
Met primary endpoint
registry Standard Treatment Plus Nicorandil vs Standard Treatment; p =0.0086; Ratio 0.503 (95% CI 0.301 to 0.840) NCT01396395 ↗
paper CONCLUSION: Nicorandil significantly reduced the number of ischemic attacks when added to standard antianginal treatment PMID 27657471 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicorandil | Other / unclassified | 5 mg | Oral |
| Background | Aspirin | Small molecule | — | — |